Lifeward (Formerly ReWalk Robotics): Company Profile

Lifeward Ltd. (Nasdaq: LFWD) — formerly ReWalk Robotics — has spent a decade building the regulatory and reimbursement infrastructure that most medical device companies treat as a prerequisite for commercialization. With Medicare reimbursement finalized at $94,617 per unit, dual FDA and CE clearances secured for its seventh-generation exoskeleton, and approvals now in hand from UnitedHealthcare, Humana, and the first major U.S. commercial insurer, the structural barriers that suppressed exoskeleton adoption for years are materially lower than they were 18 months ago. The question is whether a ~$9M market-cap company with persistent operating losses and a missed 2024 revenue target can execute the commercial scaling that those milestones theoretically enable.

Business Overview

Rebranded from ReWalk Robotics in January 2024 under Nasdaq ticker LFWD, Lifeward operates across three product lines: powered personal exoskeletons for spinal cord injury, soft exo-suits for post-stroke rehabilitation, and anti-gravity treadmills acquired through the $19M purchase of AlterG in August 2023. The AlterG acquisition nearly doubled reported revenue — from $13.85M in 2023 to $25.66M in 2024 — but also introduced integration complexity and missed the company’s own $28–$32M guidance range. A January 2026 transaction with Oramed Pharmaceuticals, which transfers Oramed’s POD oral drug delivery platform to Lifeward in exchange for up to 49.9% beneficial ownership, adds further strategic complexity and governance concentration risk. Mark Grant, a former Medtronic diabetes executive, is replacing CEO Larry Jasinski as part of that transaction.

Technology and Product Portfolio

Product	Status	Key Regulatory Milestones	Price/Rate
ReWalk 7 Personal Exoskeleton	FIELDED	FDA 510(k) Mar 2025; CE Mark Sep 2025	$94,617 Medicare rate
ReStore Soft Exo-Suit	CLINICAL	CE Mark pending Q2 2026	TBD
AlterG Anti-Gravity Treadmill	FIELDED	FDA 510(k) (legacy); CE Mark	$45K–$65K per unit

Reimbursement and Market Access

The Medicare reimbursement decision represents the category’s inflection point. At $94,617 per unit, the ReWalk 7 pricing aligns with orthopedic surgical intervention costs, making institutional procurement economically defensible for rehabilitation centers and hospital systems. Commercial insurer approvals from UnitedHealthcare and Humana signal that payer risk models have shifted: exoskeletons are now evaluated as functional restoration devices rather than experimental technology.

However, reimbursement approval does not guarantee utilization. Lifeward must demonstrate that clinical outcomes data, patient selection protocols, and therapist training infrastructure can sustain the volume assumptions embedded in its $28–$32M 2024 guidance. The missed 2024 target suggests execution gaps remain.

Financial Position and Strategic Risk

With a market capitalization near $9M and cumulative operating losses, Lifeward operates with limited financial runway. The Oramed transaction introduces governance complexity: a 49.9% beneficial ownership stake by a pharmaceutical company with different commercial incentives and capital structures creates potential conflicts in strategic prioritization and capital allocation. CEO transition to Mark Grant, while bringing Medtronic-scale commercial experience, signals management instability during a critical scaling phase.

Outlook

Lifeward’s regulatory and reimbursement achievements are genuine and material. The institutional barriers to exoskeleton adoption have measurably lowered. The defining test is whether the company can convert those structural advantages into sustainable revenue growth and positive unit economics before capital constraints force strategic concessions or restructuring.